title: Maintenance or eradication of residual disease in indolent lymphoma: where do we stand?
authors.forename: Anton
authors.initials: A
authors.lastname: Hagenbeek
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D018365:Neoplasm, Residual / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents